Edge falls off the cliff as Phase III trial flops

28 March 2018
2019_biotech_test_vial_discovery_big

US biotech Edge Therapeutics (Nasdaq: EDGE) saw its share price drop by 92% on Wednesday, with its value scraping along at $1.22 at lunchtime.

It follows the company’s announcement on discouraging data from pre-specified interim analysis from the day 90 visit of the first 210 subjects randomized and treated in the Phase III NEWTON 2 study of its lead product, EG-1962, in adults with aneurysmal subarachnoid hemorrhage (aSAH).

The independent Data Monitoring Committee (DMC) recommended that the study be stopped based on its conclusion that the study has a low probability of meeting its primary endpoint.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology